Cardiomyopathy in obesity, insulin resistance and diabetes

Journal of Physiology

Volumn 598, Issue 14, 2020, Pages 2977-2993

  Nakamura, Michinari ^a   Sadoshima, Junichi ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

cardiomyopathy; diabetes; dyslipidemia; fatty acid; fibrate; hypertriglyceridemia; insulin resistance; lipid accumulation; lipotoxicity; obesity; PPAR

Indexed keywords

ACYLCARNITINE; ANAKINRA; ANGIOPOIETIN LIKE 3 PROTEIN; ANGIOPOIETIN RELATED PROTEIN; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; CANAKINUMAB; CERAMIDE; DIACYLGLYCEROL; EMPAGLIFLOZIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3ALPHA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; LIRAGLUTIDE; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PEMAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; SEMAGLUTIDE; SIMVASTATIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACYLATION; ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASYMPTOMATIC DISEASE; ATHEROSCLEROSIS; BODY WEIGHT LOSS; CALCIUM SIGNALING; CALORIC RESTRICTION; CARBOHYDRATE DIET; CARBOTOXICITY; CARDIAC STEATOSIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL DEATH; CELL DIFFERENTIATION; CITRIC ACID CYCLE; COMORBIDITY; CONFERENCE PAPER; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; DIET SUPPLEMENTATION; DIMERIZATION; DISEASE ASSOCIATION; DISEASE BURDEN; DISEASE CLASSIFICATION; DISEASE RISK ASSESSMENT; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG POTENTIATION; DRUG TARGETING; DYSLIPIDEMIA; EARLY INTERVENTION; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; EXTRACELLULAR MATRIX; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GASTRECTOMY; GASTRIC BANDING; GASTRIC BYPASS SURGERY; GENE MUTATION; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE OXIDATION; GLYCEMIC CONTROL; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEREDITY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNE RESPONSE; INFLAMMATION; INSULIN RESISTANCE; INSULIN RESISTANCE INDUCED CARDIOMYOPATHY; LACK OF DRUG EFFECT; LIPID COMPOSITION; LIPID STORAGE; LIPIDOSIS; LIPOGENESIS; LIPOTOXIC CARDIOMYOPATHY; LIPOTOXICITY; METABOLIC CARDIOMYOPATHY; METABOLIC DISORDER; MONOTHERAPY; MORTALITY RISK; MYOCARDITIS; NON HYPERTENSIVE CARDIOMYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONISCHEMIC CARDIOMYOPATHY; OBESITY; OBESITY RELATED CARDIOMYOPATHY; OXIDATION REDUCTION REACTION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARTIAL DRUG RESPONSE; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PROTEIN TRANSPORT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; RISK REDUCTION; SIGNAL TRANSDUCTION; STEATOSIS; SYSTOLIC DYSFUNCTION; TRANSCRIPTION REGULATION; CARDIAC MUSCLE; COMPLICATION; LIPID METABOLISM; METABOLISM;

DIABETES MELLITUS; DIABETIC CARDIOMYOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPID METABOLISM; MYOCARDIUM; OBESITY;

EID: 85063964768     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/JP276747     Document Type: Conference Paper

References (155)

1. Aasum E, Khalid AM, Gudbrandsen OA, How OJ, Berge RK & Larsen TS (2008). Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice. J Mol Cell Cardiol 44, 201–209.
2. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG & Byington RP (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362, 1563–1574.
3. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG & Friedewald WT (2008). Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358, 2545–2559.
4. Adams TD, Davidson LE, Litwin SE, Kim J, Kolotkin RL, Nanjee MN, Gutierrez JM, Frogley SJ, Ibele AR, Brinton EA, Hopkins PN, McKinlay R, Simper SC & Hunt SC (2017). Weight and metabolic outcomes 12 years after gastric bypass. N Engl J Med 377, 1143–1155.
5. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R & Travert F (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358, 2560–2572.
6. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF & Sadoshima J (2008). A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978–993.
7. Ahmad T, Kelly JP, McGarrah RW, Hellkamp AS, Fiuzat M, Testani JM, Wang TS, Verma A, Samsky MD, Donahue MP, Ilkayeva OR, Bowles DE, Patel CB, Milano CA, Rogers JG, Felker GM, O'Connor CM, Shah SH & Kraus WE (2016). Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J Am Coll Cardiol 67, 291–299.
8. Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, Simes J, Tonkin AM, Sullivan DR, Barnes EH, Nestel PJ, Kingwell BA, Marre M, Neal B, Poulter NR, Rodgers A, Williams B, Zoungas S, Hillis GS, Chalmers J, Woodward M & Meikle PJ (2016). Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation 134, 1637–1650.
9. Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H & Ishibashi S (2018). Effects of pemafibrate, a novel selective PPARα modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 41, 538–546.
10. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu PH, Rybkin II, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS & Spiegelman BM (2005). Transcriptional coactivator PGC-1α controls the energy state and contractile function of cardiac muscle. Cell Metab 1, 259–271.
11. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A & Spiegelman BM (2006). Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-γ coactivator 1α. Proc Natl Acad Sci U S A 103, 10086–10091.
12. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S & Armitage J (2018). Effects of n−3 fatty acid supplements in diabetes mellitus. N Engl J Med 379, 1540–1550.
13. Authors/Task Force Members, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, Deaton C, Escaned J, Hammes HP, Huikuri H, Marre M, Marx N, Mellbin L, Ostergren J, Patrono C, Seferovic P, Uva MS, Taskinen MR, Tendera M, Tuomilehto J, Valensi P, Zamorano JL, ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Document R, De Backer G, Sirnes PA, Ezquerra EA, Avogaro A, Badimon L, Baranova E, Baumgartner H, Betteridge J, Ceriello A, Fagard R, Funck-Brentano C, Gulba DC, Hasdai D, Hoes AW, Kjekshus JK, Knuuti J, Kolh P, Lev E, Mueller C, Neyses L, Nilsson PM, Perk J, Ponikowski P, Reiner Z, Sattar N, Schachinger V, Scheen A, Schirmer H, Stromberg A, Sudzhaeva S, Tamargo JL, Viigimaa M, Vlachopoulos C & Xuereb RG (2013). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34, 3035–3087.
14. Barger PM, Brandt JM, Leone TC, Weinheimer CJ & Kelly DP (2000). Deactivation of peroxisome proliferator-activated receptor-α during cardiac hypertrophic growth. J Clin Invest 105, 1723–1730.
15. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM & Investigators R-I (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med 380, 11–22.
16. Bikman BT & Summers SA (2011). Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest 121, 4222–4230.
17. Bozkurt B, Aguilar D, Deswal A, Dunbar SB, Francis GS, Horwich T, Jessup M, Kosiborod M, Pritchett AM, Ramasubbu K, Rosendorff C, Yancy C; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Hypertension; Council on Quality and Outcomes Research (2016). Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: A scientific statement from the American Heart Association. Circulation 134, e535–e578.
18. Braunwald E (2015). The war against heart failure: The lancet lecture. Lancet 385, 812–824.
19. Bray GA, Fruhbeck G, Ryan DH & Wilding JP (2016). Management of obesity. Lancet 387, 1947–1956.
20. Brown DA, Perry JB, Allen ME, Sabbah HN, Stauffer BL, Shaikh SR, Cleland JG, Colucci WS, Butler J, Voors AA, Anker SD, Pitt B, Pieske B, Filippatos G, Greene SJ & Gheorghiade M (2017). Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol 14, 238–250.
21. Campbell RT, Jhund PS, Castagno D, Hawkins NM, Petrie MC & McMurray JJ (2012). What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE? J Am Coll Cardiol 60, 2349–2356.
22. 2+ regulation, are associated with a high-fat diet-induced improvement in contractile function in heart failure. Am J Physiol Heart Circ Physiol 301, H1438–H1446.
23. Chiu HC, Kovacs A, Blanton RM, Han X, Courtois M, Weinheimer CJ, Yamada KA, Brunet S, Xu H, Nerbonne JM, Welch MJ, Fettig NM, Sharp TL, Sambandam N, Olson KM, Ory DS & Schaffer JE (2005). Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ Res 96, 225–233.
24. Chokshi A, Drosatos K, Cheema FH, Ji R, Khawaja T, Yu S, Kato T, Khan R, Takayama H, Knoll R, Milting H, Chung CS, Jorde U, Naka Y, Mancini DM, Goldberg IJ & Schulze PC (2012). Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125, 2844–2853.
25. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J & Collins R (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670–1681.
26. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S & Peto R (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388, 2532–2561.
27. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER & Howard BV (2000). Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101, 2271–2276.
28. Dewey FE, Gusarova V, Dunbar RL, O'Dushlaine C, Schurmann C, Gottesman O, McCarthy S, Van Hout CV, Bruse S, Dansky HM, Leader JB, Murray MF, Ritchie MD, Kirchner HL, Habegger L, Lopez A, Penn J, Zhao A, Shao W, Stahl N, Murphy AJ, Hamon S, Bouzelmat A, Zhang R, Shumel B, Pordy R, Gipe D, Herman GA, Sheu WHH, Lee IT, Liang KW, Guo X, Rotter JI, Chen YI, Kraus WE, Shah SH, Damrauer S, Small A, Rader DJ, Wulff AB, Nordestgaard BG, Tybjaerg-Hansen A, van den Hoek AM, Princen HMG, Ledbetter DH, Carey DJ, Overton JD, Reid JG, Sasiela WJ, Banerjee P, Shuldiner AR, Borecki IB, Teslovich TM, Yancopoulos GD, Mellis SJ, Gromada J & Baras A (2017). Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med 377, 211–221.
29. Ding D, Lawson KD, Kolbe-Alexander TL, Finkelstein EA, Katzmarzyk PT, van Mechelen W, Pratt M & Lancet Physical Activity Series 2 Executive Committee (2016). The economic burden of physical inactivity: a global analysis of major non-communicable diseases. Lancet 388, 1311–1324.
30. Dong B, Qi D, Yang L, Huang Y, Xiao X, Tai N, Wen L & Wong FS (2012). TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. Am J Physiol Heart Circ Physiol 303, H732–H742.
31. Downing NS, Cheng T, Krumholz HM, Shah ND & Ross JS (2014). Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis. JAMA Intern Med 174, 1176–1182.
32. Duncan JG, Fong JL, Medeiros DM, Finck BN & Kelly DP (2007). Insulin-resistant heart exhibits a mitochondrial biogenic response driven by the peroxisome proliferator-activated receptor-α/PGC-1α gene regulatory pathway. Circulation 115, 909–917.
33. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, Yagi N, Ohto U, Kimoto M, Miyake K, Tobe K, Arai H, Kadowaki T & Nagai R (2012). Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab 15, 518–533.
34. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP & Investigators AS (2017). Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. JAMA Cardiol 2, 370–380.
35. Elmariah S, Farrell LA, Furman D, Lindman BR, Shi X, Morningstar JE, Rhee EP & Gerszten RE (2018). Association of acylcarnitines with left ventricular remodeling in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. JAMA Cardiol 3, 242–246.
36. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD & Kelly DP (2002). The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 109, 121–130.
37. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG & Simmons RL (1992). Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257, 387–389.
38. Fischer J, Lefevre C, Morava E, Mussini JM, Laforet P, Negre-Salvayre A, Lathrop M & Salvayre R (2007). The gene encoding adipose triglyceride lipase (PNPLA2) is mutated in neutral lipid storage disease with myopathy. Nat Genet 39, 28–30.
39. Food and Drug Administration (2016). Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Fed Regist 81, 22612–22613.
40. Forouhi NG, Koulman A, Sharp SJ, Imamura F, Kroger J, Schulze MB, Crowe FL, Huerta JM, Guevara M, Beulens JW, van Woudenbergh GJ, Wang L, Summerhill K, Griffin JL, Feskens EJ, Amiano P, Boeing H, Clavel-Chapelon F, Dartois L, Fagherazzi G, Franks PW, Gonzalez C, Jakobsen MU, Kaaks R, Key TJ, Khaw KT, Kuhn T, Mattiello A, Nilsson PM, Overvad K, Pala V, Palli D, Quiros JR, Rolandsson O, Roswall N, Sacerdote C, Sanchez MJ, Slimani N, Spijkerman AM, Tjonneland A, Tormo MJ, Tumino R, van der AD, van der Schouw YT, Langenberg C, Riboli E & Wareham NJ (2014). Differences in the prospective association between individual plasma phospholipid saturated fatty acids and incident type 2 diabetes: the EPIC-InterAct case-cohort study. Lancet Diabetes Endocrinol 2, 810–818.
41. Forrester SJ, Kikuchi DS, Hernandes MS, Xu Q & Griendling KK (2018). Reactive oxygen species in metabolic and inflammatory signaling. Circ Res 122, 877–902.
42. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T & Nikkilä EA (1987). Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317, 1237–1245.
43. Frieler RA & Mortensen RM (2015). Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131, 1019–1030.
44. Fruchart JC (2017). Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol 16, 124.
45. GBD 2017 Risk Factor Collaborators (2018). Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1923–1994.
46. Geraldes P & King GL (2010). Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106, 1319–1331.
47. Goldberg IJ, Trent CM & Schulze PC (2012). Lipid metabolism and toxicity in the heart. Cell Metab 15, 805–812.
48. Haemmerle G, Moustafa T, Woelkart G, Buttner S, Schmidt A, van de Weijer T, Hesselink M, Jaeger D, Kienesberger PC, Zierler K, Schreiber R, Eichmann T, Kolb D, Kotzbeck P, Schweiger M, Kumari M, Eder S, Schoiswohl G, Wongsiriroj N, Pollak NM, Radner FP, Preiss-Landl K, Kolbe T, Rulicke T, Pieske B, Trauner M, Lass A, Zimmermann R, Hoefler G, Cinti S, Kershaw EE, Schrauwen P, Madeo F, Mayer B & Zechner R (2011). ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med 17, 1076–1085.
49. Harayama T & Riezman H (2018). Understanding the diversity of membrane lipid composition. Nat Rev Mol Cell Biol 19, 281–296.
50. Herrero P, Peterson LR, McGill JB, Matthew S, Lesniak D, Dence C & Gropler RJ (2006). Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 47, 598–604.
51. Hirano K, Ikeda Y, Zaima N, Sakata Y & Matsumiya G (2008). Triglyceride deposit cardiomyovasculopathy. N Engl J Med 359, 2396–2398.
52. Hotamisligil GS (2006). Inflammation and metabolic disorders. Nature 444, 860–867.
53. Hotamisligil GS (2017). Foundations of immunometabolism and implications for metabolic health and disease. Immunity 47, 406–420.
54. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S & Selby JV (2001). Glycemic control and heart failure among adult patients with diabetes. Circulation 103, 2668–2673.
55. Ji R, Akashi H, Drosatos K, Liao X, Jiang H, Kennel PJ, Brunjes DL, Castillero E, Zhang X, Deng LY, Homma S, George IJ, Takayama H, Naka Y, Goldberg IJ & Schulze PC (2017). Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight 2, 82922.
56. Jornayvaz FR & Shulman GI (2012). Diacylglycerol activation of protein kinase Cε and hepatic insulin resistance. Cell Metab 15, 574–584.
57. Kelly DP & Strauss AW (1994). Inherited cardiomyopathies. N Engl J Med 330, 913–919.
58. Kim JA, Wei Y & Sowers JR (2008). Role of mitochondrial dysfunction in insulin resistance. Circ Res 102, 401–414.
59. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group (2007). Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357, 2248–2261.
60. Ko HJ, Zhang Z, Jung DY, Jun JY, Ma Z, Jones KE, Chan SY & Kim JK (2009). Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 58, 2536–2546.
61. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, Norhammar A, Birkeland KI, Jorgensen ME, Thuresson M, Arya N, Bodegard J, Hammar N, Fenici P; CVD-REAL Investigators and Study Group (2017). Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: The CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors). Circulation 136, 249–259.
62. Kroemer G, Lopez-Otin C, Madeo F & de Cabo R (2018). Carbotoxicity-noxious effects of carbohydrates. Cell 175, 605–614.
63. Lee IM, Shiroma EJ, Lobelo F, Puska P, Blair SN, Katzmarzyk PT; Lancet Physical Activity Series Working Group (2012). Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet 380, 219–229.
64. Lee JY, Sohn KH, Rhee SH & Hwang D (2001). Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276, 16683–16689.
65. Lee YS, Wollam J & Olefsky JM (2018). An integrated view of immunometabolism. Cell 172, 22–40.
66. Leone TC & Kelly DP (2011). Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb Symp Quant Biol 76, 175–182.
67. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussinesq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovannucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hubbell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Petzold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodriguez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA & Memish ZA (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224–2260.
68. Liu G, Zheng XX, Xu YL, Ru J, Hui RT & Huang XH (2014). Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 113, 1198–1204.
69. Liu Q, Chen Y, Auger-Messier M & Molkentin JD (2012). Interaction between NFκB and NFAT coordinates cardiac hypertrophy and pathological remodeling. Circ Res 110, 1077–1086.
70. Liu Q, Docherty JC, Rendell JC, Clanachan AS & Lopaschuk GD (2002). High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 39, 718–725.
71. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE & Smith SC Jr (2017). 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol 70, 1785–1822.
72. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS & Stanley WC (2010). Myocardial fatty acid metabolism in health and disease. Physiol Rev 90, 207–258.
73. Low Wang CC, Hess CN, Hiatt WR & Goldfine AB (2016). Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation 133, 2459–2502.
74. Ludwig DS, Willett WC, Volek JS & Neuhouser ML (2018). Dietary fat: From foe to friend? Science 362, 764–770.
75. Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, Zhang M, Zhang Y & An F (2014). NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS One 9, e104771.
76. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M & Budaj A (2000). Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 102, 1014–1019.
77. Mann DL (2015). Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res 116, 1254–1268.
78. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE; VITAL Research Group (2019). Marine n−3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 380, 23–32.
79. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators (2016a). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375, 1834–1844.
80. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators (2016b). Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375, 311–322.
81. Marwick TH, Ritchie R, Shaw JE & Kaye D (2018). Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol 71, 339–351.
82. Mathur A, Sims HF, Gopalakrishnan D, Gibson B, Rinaldo P, Vockley J, Hug G & Strauss AW (1999). Molecular heterogeneity in very-long-chain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 99, 1337–1343.
83. McCoin CS, Knotts TA & Adams SH (2015). Acylcarnitines—old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol 11, 617–625.
84. 1H-magnetic resonance spectroscopy study. Circulation 116, 1170–1175.
85. Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S & Sabatine MS (2015). Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271.
86. Metra M & Teerlink JR (2017). Heart failure. Lancet 390, 1981–1995.
87. Mitra R, Nogee DP, Zechner JF, Yea K, Gierasch CM, Kovacs A, Medeiros DM, Kelly DP & Duncan JG (2012). The transcriptional coactivators, PGC-1α and β, cooperate to maintain cardiac mitochondrial function during the early stages of insulin resistance. J Mol Cell Cardiol 52, 701–710.
88. Nakamura M, Bhatnagar A & Sadoshima J (2012). Overview of pyridine nucleotides review series. Circ Res 111, 604–610.
89. Nakamura M, Liu T, Husain S, Zhai P, Warren JS, Hsu C-P, Matsuda T, Phiel CJ, Cox JE, Tian B, Li H & Sadoshima J (2019). Glycogen synthase kinase-3α promotes fatty acid uptake and lipotoxic cardiomyopathy. Cell Metabolism (in press; doi: 10.1016/j.cmet.2019.01.005).
90. Nakamura M & Sadoshima J (2018). Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol 15, 387–407.
91. Nakamura M, Yamashita T, Yajima J, Oikawa Y, Sagara K, Koike A, Kirigaya H, Nagashima K, Sawada H, Aizawa T; Shinken Database Study Group (2010). Brachial-ankle pulse wave velocity as a risk stratification index for the short-term prognosis of type 2 diabetic patients with coronary artery disease. Hypertens Res 33, 1018–1024.
92. Nassif M & Kosiborod M (2018). Effect of glucose-lowering therapies on heart failure. Nat Rev Cardiol 15, 282–291.
93. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, Glass CK, Neels JG & Olefsky JM (2007). A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 282, 35279–35292.
94. Nishida K & Otsu K (2017). Inflammation and metabolic cardiomyopathy. Cardiovasc Res 113, 389–398.
95. Nordestgaard BG (2016). Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circ Res 118, 547–563.
96. Oka T, Hikoso S, Yamaguchi O, Taneike M, Takeda T, Tamai T, Oyabu J, Murakawa T, Nakayama H, Nishida K, Akira S, Yamamoto A, Komuro I & Otsu K (2012). Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature 485, 251–255.
97. Ouchi N, Parker JL, Lugus JJ & Walsh K (2011). Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11, 85–97.
98. Paneni F & Luscher TF (2017). Cardiovascular protection in the treatment of type 2 diabetes: A review of clinical trial results across drug classes. Am J Cardiol 120, S17–S27.
99. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED & Goldberg IJ (2008). Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49, 2101–2112.
100. Patnode CD, Evans CV, Senger CA, Redmond N & Lin JS (2017). Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: Updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 318, 175–193.
101. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, Dence C, Klein S, Marsala J, Meyer T & Gropler RJ (2004). Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation 109, 2191–2196.
102. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P & Ridker PM (2018). Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J 206, 80–93.
103. Quispe R, Martin SS & Jones SR (2016). Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 23, 150–156.
104. Redfield MM (2016). Heart failure with preserved ejection fraction. N Engl J Med 375, 1868–1877.
105. Reiner Z (2017). Hypertriglyceridaemia and risk of coronary artery disease. Nat Rev Cardiol 14, 401–411.
106. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ & Group CT (2017a). Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 377, 1119–1131.
107. Ridker PM, Pradhan A, MacFadyen JG, Libby P & Glynn RJ (2012). Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 380, 565–571.
108. Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators (2017b). Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med 376, 1527–1539.
109. Rijzewijk LJ, van der Meer RW, Lamb HJ, de Jong HW, Lubberink M, Romijn JA, Bax JJ, de Roos A, Twisk JW, Heine RJ, Lammertsma AA, Smit JW & Diamant M (2009). Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol 54, 1524–1532.
110. Rijzewijk LJ, van der Meer RW, Smit JW, Diamant M, Bax JJ, Hammer S, Romijn JA, de Roos A & Lamb HJ (2008). Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol 52, 1793–1799.
111. Roberts LD, Koulman A & Griffin JL (2014). Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol 2, 65–75.
112. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH & Anderson JW (2002). Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 162, 2597–2604.
113. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW & Grishman A (1972). New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30, 595–602.
114. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376, 1713–1722.
115. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV; American Heart Association (2017). Dietary fats and cardiovascular disease: A presidential advisory from the American Heart Association. Circulation 136, e1–e23.
116. Sarma S, Ardehali H & Gheorghiade M (2012). Enhancing the metabolic substrate: PPAR-alpha agonists in heart failure. Heart Fail Rev 17, 35–43.
117. Schilling JD & Mann DL (2012). Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin 8, 619–631.
118. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 379, 2097–2107.
119. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009). Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 32, 493–498.
120. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ & Tabas I (2010). Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 12, 467–482.
121. 2+ release in myocytes from streptozotocin-induced diabetic rats. J Mol Cell Cardiol 42, 234–246.
122. Shao D, Oka S, Liu T, Zhai P, Ago T, Sciarretta S, Li H & Sadoshima J (2014). A redox-dependent mechanism for regulation of AMPK activation by Thioredoxin1 during energy starvation. Cell Metab 19, 232–245.
123. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH & Taegtmeyer H (2004). Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18, 1692–1700.
124. Sharma S, Guthrie PH, Chan SS, Haq S & Taegtmeyer H (2007). Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc Res 76, 71–80.
125. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H & Flier JS (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116, 3015–3025.
126. Sihag S, Cresci S, Li AY, Sucharov CC & Lehman JJ (2009). PGC-1α and ERRα target gene downregulation is a signature of the failing human heart. J Mol Cell Cardiol 46, 201–212.
127. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E & Sabatine MS (2016). Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA 316, 1289–1297.
128. Singh R, Barden A, Mori T & Beilin L (2001). Advanced glycation end-products: a review. Diabetologia 44, 129–146.
129. Spector AA & Yorek MA (1985). Membrane lipid composition and cellular function. J Lipid Res 26, 1015–1035.
130. Stanley WC, Dabkowski ER, Ribeiro RF Jr & O'Connell KA (2012). Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res 110, 764–776.
131. Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, Menni C, Moayyeri A, Santer P, Rungger G, Spector TD, Willeit J, Kiechl S & Mayr M (2014). Lipidomics profiling and risk of cardiovascular disease in the prospective population-based Bruneck study. Circulation 129, 1821–1831.
132. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT & Moore KJ (2010). CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 11, 155–161.
133. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC & Holman RR (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321, 405–412.
134. Sverdlov AL, Elezaby A, Qin F, Behring JB, Luptak I, Calamaras TD, Siwik DA, Miller EJ, Liesa M, Shirihai OS, Pimentel DR, Cohen RA, Bachschmid MM & Colucci WS (2016). Mitochondrial reactive oxygen species mediate cardiac structural, functional, and mitochondrial consequences of diet-induced metabolic heart disease. J Am Heart Assoc 5, e002555.
135. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G & Gissi HFI (2008). Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231–1239.
136. Thaik CM, Calderone A, Takahashi N & Colucci WS (1995). Interleukin-1β modulates the growth and phenotype of neonatal rat cardiac myocytes. J Clin Invest 96, 1093–1099.
137. Thomas CM, Yong QC, Rosa RM, Seqqat R, Gopal S, Casarini DE, Jones WK, Gupta S, Baker KM & Kumar R (2014). Cardiac-specific suppression of NF-κB signaling prevents diabetic cardiomyopathy via inhibition of the renin-angiotensin system. Am J Physiol Heart Circ Physiol 307, H1036–H1045.
138. Tocchetti CG, Caceres V, Stanley BA, Xie C, Shi S, Watson WH, O'Rourke B, Spadari-Bratfisch RC, Cortassa S, Akar FG, Paolocci N & Aon MA (2012). GSH or palmitate preserves mitochondrial energetic/redox balance, preventing mechanical dysfunction in metabolically challenged myocytes/hearts from type 2 diabetic mice. Diabetes 61, 3094–3105.
139. Tong X, Hou X, Jourd'heuil D, Weisbrod RM & Cohen RA (2010). Upregulation of Nox4 by TGFβ1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. Circ Res 107, 975–983.
140. Tsujimoto T & Kajio H (2017). Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol 70, 2739–2749.
141. Ussher JR, Jaswal JS & Lopaschuk GD (2012). Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ Res 111, 628–641.
142. Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA & Abbate A (2014). Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113, 321–327.
143. Vega RB & Kelly DP (2017). Cardiac nuclear receptors: architects of mitochondrial structure and function. J Clin Invest 127, 1155–1164.
144. Venalainen TM, Viitasalo AM, Schwab US, Eloranta AM, Haapala EA, Jalkanen HP, de Mello VD, Laaksonen DE, Lindi VI, Agren JJ & Lakka TA (2016). Effect of a 2-y dietary and physical activity intervention on plasma fatty acid composition and estimated desaturase and elongase activities in children: the Physical Activity and Nutrition in Children Study. Am J Clin Nutr 104, 964–972.
145. Vos MB, Kaar JL, Welsh JA, Van Horn LV, Feig DI, Anderson CAM, Patel MJ, Cruz Munos J, Krebs NF, Xanthakos SA, Johnson RK; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; Council on Hypertension (2017). Added sugars and cardiovascular disease risk in children: A scientific statement from the American Heart Association. Circulation 135, e1017–e1034.
146. Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ & Ting JP (2011). Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12, 408–415.
147. Woodiwiss AJ, Libhaber CD, Majane OH, Libhaber E, Maseko M & Norton GR (2008). Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 21, 1144–1151.
148. Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE & Smith SC Jr (2016). 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: A report of the American college of cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 68, 92–125.
149. Wu L & Parhofer KG (2014). Diabetic dyslipidemia. Metabolism 63, 1469–1479.
150. Wurtz P, Havulinna AS, Soininen P, Tynkkynen T, Prieto-Merino D, Tillin T, Ghorbani A, Artati A, Wang Q, Tiainen M, Kangas AJ, Kettunen J, Kaikkonen J, Mikkila V, Jula A, Kahonen M, Lehtimaki T, Lawlor DA, Gaunt TR, Hughes AD, Sattar N, Illig T, Adamski J, Wang TJ, Perola M, Ripatti S, Vasan RS, Raitakari OT, Gerszten RE, Casas JP, Chaturvedi N, Ala-Korpela M & Salomaa V (2015). Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 131, 774–785.
151. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S & Goldberg IJ (2003). Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111, 419–426.
152. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62, e147–e239.
153. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators (2007). Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369, 1090–1098.
154. Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH & Sabatine MS (2019). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393, 31–39.
155. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373, 2117–2128.